The move comes less than a year after the company attempted to save $1.5 billion through the layoff of some 2,200 employees.

Bristol Myers Squibb will make even deeper cuts to its organization to enhance efficiencies as it faces the 2028 loss of ...

Bristol-Myers Squibb (SMY) stock falls as its Q4 2024 results beat Street forecasts, but its 2025 outlook fell short of ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

On a per-share basis, the Princeton, New Jersey-based company said it had net income of 4 cents. Earnings, adjusted for non-recurring costs, came to $1.67 per share. The results surpassed Wall Street ...

Last year, Bristol Myers Squibb devoted half a page of its annual report to its diversity, equity and inclusion efforts, ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best drug stocks ...

Bristol Myers Squibb will cut $2 billion in costs by the ... allowing the company to invest in new drugs and research. The company previously outlined plans to cut $1.5 billion by 2025, which ...

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis: Princeton, New Jersey Tuesday, February 18, 2025, 1 ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...